drugset / Trial / NCT04334408

Safety and Efficacy of Fremanezumab for Migraine in Adult CADASIL

NCT04334408

Phase 2 Withdrawn Mayo Clinic
RandomizedCrossoverDouble-blindTreatment

Summary

Researchers are trying to find out more about the side effects of fremanezumab when treating patients with Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) for migraine headaches.

Timeline

Start
2021-12
Primary completion
2024-12
Completion
2024-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Fremanezumab Monoclonal antibody 225 mg Subcutaneous